What did @jenn_mel_ actually say?
A New Jersey teacher with 451K views on this clip says Wegovy cost her 20 pounds but also her muscle tone, leaving her with skin that "hangs and wobbles" when she walks. She says she went from being an "avid avid avid exerciser" to being too exhausted to work out consistently over the past year, and she now refuses to wear shorts or a bathing suit. She frames this as a trade-off: the drug worked for appetite suppression, but the physical cost was unexpected and embarrassing.
This is a personal experience video, not a medical claim video, and she's careful to say "at least for me" and "these were my experiences." That matters for how we evaluate it. She is not telling you to stop taking Wegovy. She is telling you what happened to her body, which is a different thing.
Does the science back this up?
Yes, more than most people want to admit. The muscle loss concern is real and documented. The STEP trials showed that roughly 40% of weight lost on semaglutide is lean mass, not fat. That is not a fringe finding.
Researchers Wilding et al. (2021, NEJM) reported significant total weight loss in STEP 1, but body composition data from associated studies showed lean mass losses that concerned clinicians even as the headline numbers looked good. A 2023 analysis by Bikou et al. in the Journal of Cachexia, Sarcopenia and Muscle specifically flagged GLP-1 receptor agonist-induced muscle loss as a clinical concern warranting resistance training protocols. The fatigue she describes is also consistent with the drug's known side effect profile. Nausea, fatigue, and reduced caloric intake together create a pretty hostile environment for maintaining an exercise routine. If you're eating far less and feeling wiped out, you are not going to the gym, and that means muscle loss accelerates. She's describing a real physiological cascade, not a fluke.
What did they get wrong (or right)?
She got the core experience right. Where the framing gets imprecise is in attributing the muscle loss solely to Wegovy as if the drug directly consumed her muscle. The more accurate picture is that the drug suppressed her appetite aggressively, she ate less, she was too fatigued to exercise, and the combination of caloric deficit plus muscle disuse caused the lean mass loss. The drug is implicated, but it is not acting like some muscle-eating parasite.
This is not a trivial distinction. Patients who maintain resistance training on GLP-1 drugs show substantially better lean mass preservation. Cava et al. (2017, Advances in Nutrition) documented this pattern across multiple caloric restriction studies: protein intake and resistance exercise are the two biggest protective factors against lean mass loss regardless of how you create the deficit. The drug made both of those harder for her. That is a real problem. But it is a solvable problem with clinical support, not an inevitable outcome.
She also does not mention protein intake at all, which is a significant omission when discussing body composition changes on a GLP-1 drug.
What should you actually know?
If you are on or considering a GLP-1 medication, the loose skin and muscle loss issue is not a myth to dismiss. It is a known, documented risk that your prescriber should be discussing with you before you start, not after you are standing in a mumu.
- Roughly one-third to one-half of weight lost on semaglutide can be lean mass if no countermeasures are taken, per multiple body composition analyses.
- Protein intake recommendations for people on GLP-1 drugs typically run higher than standard guidelines, often 1.2 to 1.6 grams per kilogram of body weight, to offset muscle loss risk.
- Resistance training is the single most evidence-supported intervention for preserving muscle during weight loss. Villareal et al. (2017, NEJM) showed this clearly in older adults losing weight.
- Fatigue is a real side effect that can break the exercise habit, and clinicians should be proactively addressing this, not waiting for patients to report it six months in.
- Loose skin after significant weight loss is largely a function of age, speed of loss, and skin elasticity. It is not reversible with diet or exercise once it has occurred.
Her video is doing something useful: showing the cosmetic and functional trade-offs that do not show up in clinical trial endpoints. Weight loss trials measure the scale. They do not measure whether you feel confident in shorts.
The bottom line
@jenn_mel_ is describing a real and underreported consequence of GLP-1-driven weight loss. The science supports her core experience. The drug's mechanism creates conditions that make muscle preservation genuinely difficult. She oversimplifies the cause slightly by not factoring in the exercise drop-off and likely reduced protein intake, but the clinical concern she is raising is legitimate. Prescribers and patients both need to take body composition, not just body weight, seriously from day one on these medications.